Company profile: Delcath Systems
1.1 - Company Overview
Company description
- Provider of interventional oncology therapies for metastatic liver cancer, including HEPZATO KIT for adult patients with metastatic uveal melanoma using a hepatic delivery system; the CHEMOSAT Hepatic Delivery System for melphalan for percutaneous hepatic perfusion to treat liver cancers; and Percutaneous Hepatic Perfusion, a minimally invasive procedure delivering high-dose chemotherapy directly to the liver while isolating the organ from the body’s circulatory system.
Products and services
- CHEMOSAT® Hepatic Delivery System for Melphalan: A clinical-grade medical device enabling percutaneous hepatic perfusion with melphalan to target and treat liver cancers via controlled hepatic delivery
- HEPZATO KIT™: A kit-based treatment for adult patients with metastatic Uveal Melanoma, combining an injection with a hepatic delivery system for targeted liver administration
- Percutaneous Hepatic Perfusion (PHP): A minimally invasive procedure delivering high-dose chemotherapy directly to the liver while isolating the organ from the body’s circulatory system for localized perfusion
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Delcath Systems
Secretome Therapeutics
HQ: United States
Website
- Description: Provider of neonatal mesenchymal stem cell-based therapeutics and secretome-based regenerative therapies for heart failure and neurodegenerative and dermatological diseases, including STM-01 for adult and pediatric heart failure and NEO2001 for chronic ischemic heart failure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Secretome Therapeutics company profile →
Ratio Therapeutics
HQ: United States
Website
- Description: Provider of clinical-phase radiopharmaceuticals for solid tumors, with the Trillium platform for pharmacokinetic modulation to improve tumor-targeted delivery, the Macropa chelator for actinium-225 conjugation, FAP-targeted therapies including a PET diagnostic, and a Granzyme B PET imaging agent to monitor immune response in cancer and inflammatory diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ratio Therapeutics company profile →
TAE Life Sciences
HQ: United States
Website
- Description: Provider of biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT), offering the Alphabeam compact hospital-use tandem accelerator neutron source, BNCT combining boron-10 drugs and neutron beams to selectively destroy cancer cells, and TC220, a boronated amino acid analog targeting cancers including GBM, breast, and melanoma; the only company with comprehensive target drug and neutron technology product.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TAE Life Sciences company profile →
Proteomedix
HQ: Switzerland
Website
- Description: Provider of blood-based prostate cancer diagnostics, notably Proclarix: a test panel that integrates biomarkers and patient data to compute a risk score for high-grade prostate cancer using samples taken for PSA testing. Clinical evidence from 955 subjects shows Proclarix reduces unnecessary biopsies by accurately detecting clinically significant cancer; offers biomarker signatures for diagnosis, prognosis, and therapy management.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Proteomedix company profile →
Carrick Therapeutics
HQ: Ireland
Website
- Description: Provider of cancer therapeutics targeting molecular pathways driving aggressive and resistant cancers. Pipeline includes Samuraciclib (CT7001), an oral CDK7 inhibitor in clinical development for HR+, HER2- advanced breast cancer and triple negative breast cancer, and a CDK12/13 inhibitor/Cyclin-K glue-degrader in IND enabling toxicology studies targeting genomic stability and DNA repair.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Carrick Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Delcath Systems
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Delcath Systems
2.2 - Growth funds investing in similar companies to Delcath Systems
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Delcath Systems
4.2 - Public trading comparable groups for Delcath Systems
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →